期刊
BIOMEDICINE & PHARMACOTHERAPY
卷 101, 期 -, 页码 458-477出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2018.02.108
关键词
Metastatic breast cancer; Chemotherapy; Efficacy; Toxicity; Resistance; Antimetabolites; Immunologic therapy; Hormonal/endocrine therapy; DNA alkylating agents; Ion modulators; Antimitotic agents
资金
- Slovak Research and Development Agency [APVV-16-0021]
- Scientific Grant Agency of the Ministry of Education of the Slovak Republic [VEGA 1/0124/17]
- project CENTER OF TRANSLATIONAL MEDICINE [ITMS: 26220220021]
- EU sources
- European Regional Development Fund
Breast cancer is the second greatest cause of death among women worldwide; it comprises a group of heterogeneous diseases that evolves due to uncontrolled cellular growth and differentiation and the loss of normal programmed cell death. There are different molecular sub-types of breast cancer; therefore, various options are selected for treatment of different forms of metastatic breast cancer. However, the use of chemotherapeutic drugs is usually accompanied by deleterious side effects and the development of drug resistance when applied for a longer period. This review offers a classification of these chemotherapeutic agents according to their modes of action and therefore improves the understanding of molecular targets that are affected during treatment. Overall, it will allow the clinician to identify more specific targets to increase the effectiveness of a drug and to reduce general toxicity, resistance and other side effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据